The Market Reports

Index

1 RNA-based Biopharmaceuticals Market Overview
1.1 Product Overview and Scope of RNA-based Biopharmaceuticals
1.2 RNA-based Biopharmaceuticals Segment by Type
1.2.1 Global RNA-based Biopharmaceuticals Sales Growth Rate Comparison by Type (2022-2028)
1.2.2 Therapeutics
1.2.3 Vaccines
1.3 RNA-based Biopharmaceuticals Segment by Application
1.3.1 Global RNA-based Biopharmaceuticals Sales Comparison by Application: (2022-2028)
1.3.2 Cancer
1.3.3 Diabetes
1.3.4 Tuberculosis
1.3.5 Cardiovascular Diseases
1.3.6 Others
1.4 Global RNA-based Biopharmaceuticals Market Size Estimates and Forecasts
1.4.1 Global RNA-based Biopharmaceuticals Revenue 2017-2028
1.4.2 Global RNA-based Biopharmaceuticals Sales 2017-2028
1.4.3 RNA-based Biopharmaceuticals Market Size by Region: 2017 Versus 2021 Versus 2028
2 RNA-based Biopharmaceuticals Market Competition by Manufacturers
2.1 Global RNA-based Biopharmaceuticals Sales Market Share by Manufacturers (2017-2022)
2.2 Global RNA-based Biopharmaceuticals Revenue Market Share by Manufacturers (2017-2022)
2.3 Global RNA-based Biopharmaceuticals Average Price by Manufacturers (2017-2022)
2.4 Manufacturers RNA-based Biopharmaceuticals Manufacturing Sites, Area Served, Product Type
2.5 RNA-based Biopharmaceuticals Market Competitive Situation and Trends
2.5.1 RNA-based Biopharmaceuticals Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest RNA-based Biopharmaceuticals Players Market Share by Revenue
2.5.3 Global RNA-based Biopharmaceuticals Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 RNA-based Biopharmaceuticals Retrospective Market Scenario by Region
3.1 Global RNA-based Biopharmaceuticals Retrospective Market Scenario in Sales by Region: 2017-2022
3.2 Global RNA-based Biopharmaceuticals Retrospective Market Scenario in Revenue by Region: 2017-2022
3.3 North America RNA-based Biopharmaceuticals Market Facts & Figures by Country
3.3.1 North America RNA-based Biopharmaceuticals Sales by Country
3.3.2 North America RNA-based Biopharmaceuticals Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe RNA-based Biopharmaceuticals Market Facts & Figures by Country
3.4.1 Europe RNA-based Biopharmaceuticals Sales by Country
3.4.2 Europe RNA-based Biopharmaceuticals Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific RNA-based Biopharmaceuticals Market Facts & Figures by Region
3.5.1 Asia Pacific RNA-based Biopharmaceuticals Sales by Region
3.5.2 Asia Pacific RNA-based Biopharmaceuticals Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America RNA-based Biopharmaceuticals Market Facts & Figures by Country
3.6.1 Latin America RNA-based Biopharmaceuticals Sales by Country
3.6.2 Latin America RNA-based Biopharmaceuticals Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa RNA-based Biopharmaceuticals Market Facts & Figures by Country
3.7.1 Middle East and Africa RNA-based Biopharmaceuticals Sales by Country
3.7.2 Middle East and Africa RNA-based Biopharmaceuticals Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 Global RNA-based Biopharmaceuticals Historic Market Analysis by Type
4.1 Global RNA-based Biopharmaceuticals Sales Market Share by Type (2017-2022)
4.2 Global RNA-based Biopharmaceuticals Revenue Market Share by Type (2017-2022)
4.3 Global RNA-based Biopharmaceuticals Price by Type (2017-2022)
5 Global RNA-based Biopharmaceuticals Historic Market Analysis by Application
5.1 Global RNA-based Biopharmaceuticals Sales Market Share by Application (2017-2022)
5.2 Global RNA-based Biopharmaceuticals Revenue Market Share by Application (2017-2022)
5.3 Global RNA-based Biopharmaceuticals Price by Application (2017-2022)
6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Corporation Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer RNA-based Biopharmaceuticals Sales, Revenue and Gross Margin (2017-2022)
6.1.4 Pfizer RNA-based Biopharmaceuticals Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 Roche
6.2.1 Roche Corporation Information
6.2.2 Roche Description and Business Overview
6.2.3 Roche RNA-based Biopharmaceuticals Sales, Revenue and Gross Margin (2017-2022)
6.2.4 Roche RNA-based Biopharmaceuticals Product Portfolio
6.2.5 Roche Recent Developments/Updates
6.3 Sanofi-Aventis
6.3.1 Sanofi-Aventis Corporation Information
6.3.2 Sanofi-Aventis Description and Business Overview
6.3.3 Sanofi-Aventis RNA-based Biopharmaceuticals Sales, Revenue and Gross Margin (2017-2022)
6.3.4 Sanofi-Aventis RNA-based Biopharmaceuticals Product Portfolio
6.3.5 Sanofi-Aventis Recent Developments/Updates
6.4 Abbott Laboratories
6.4.1 Abbott Laboratories Corporation Information
6.4.2 Abbott Laboratories Description and Business Overview
6.4.3 Abbott Laboratories RNA-based Biopharmaceuticals Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Abbott Laboratories RNA-based Biopharmaceuticals Product Portfolio
6.4.5 Abbott Laboratories Recent Developments/Updates
6.5 Arrowhead Pharmaceuticals
6.5.1 Arrowhead Pharmaceuticals Corporation Information
6.5.2 Arrowhead Pharmaceuticals Description and Business Overview
6.5.3 Arrowhead Pharmaceuticals RNA-based Biopharmaceuticals Sales, Revenue and Gross Margin (2017-2022)
6.5.4 Arrowhead Pharmaceuticals RNA-based Biopharmaceuticals Product Portfolio
6.5.5 Arrowhead Pharmaceuticals Recent Developments/Updates
6.6 Benitec Biopharma
6.6.1 Benitec Biopharma Corporation Information
6.6.2 Benitec Biopharma Description and Business Overview
6.6.3 Benitec Biopharma RNA-based Biopharmaceuticals Sales, Revenue and Gross Margin (2017-2022)
6.6.4 Benitec Biopharma RNA-based Biopharmaceuticals Product Portfolio
6.6.5 Benitec Biopharma Recent Developments/Updates
6.7 Calimmune Inc
6.6.1 Calimmune Inc Corporation Information
6.6.2 Calimmune Inc Description and Business Overview
6.6.3 Calimmune Inc RNA-based Biopharmaceuticals Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Calimmune Inc RNA-based Biopharmaceuticals Product Portfolio
6.7.5 Calimmune Inc Recent Developments/Updates
6.8 Dicerna
6.8.1 Dicerna Corporation Information
6.8.2 Dicerna Description and Business Overview
6.8.3 Dicerna RNA-based Biopharmaceuticals Sales, Revenue and Gross Margin (2017-2022)
6.8.4 Dicerna RNA-based Biopharmaceuticals Product Portfolio
6.8.5 Dicerna Recent Developments/Updates
6.9 Gradalis
6.9.1 Gradalis Corporation Information
6.9.2 Gradalis Description and Business Overview
6.9.3 Gradalis RNA-based Biopharmaceuticals Sales, Revenue and Gross Margin (2017-2022)
6.9.4 Gradalis RNA-based Biopharmaceuticals Product Portfolio
6.9.5 Gradalis Recent Developments/Updates
6.10 Quark
6.10.1 Quark Corporation Information
6.10.2 Quark Description and Business Overview
6.10.3 Quark RNA-based Biopharmaceuticals Sales, Revenue and Gross Margin (2017-2022)
6.10.4 Quark RNA-based Biopharmaceuticals Product Portfolio
6.10.5 Quark Recent Developments/Updates
6.11 RXi
6.11.1 RXi Corporation Information
6.11.2 RXi RNA-based Biopharmaceuticals Description and Business Overview
6.11.3 RXi RNA-based Biopharmaceuticals Sales, Revenue and Gross Margin (2017-2022)
6.11.4 RXi RNA-based Biopharmaceuticals Product Portfolio
6.11.5 RXi Recent Developments/Updates
6.12 Senesco
6.12.1 Senesco Corporation Information
6.12.2 Senesco RNA-based Biopharmaceuticals Description and Business Overview
6.12.3 Senesco RNA-based Biopharmaceuticals Sales, Revenue and Gross Margin (2017-2022)
6.12.4 Senesco RNA-based Biopharmaceuticals Product Portfolio
6.12.5 Senesco Recent Developments/Updates
6.13 Silence Therapeutics
6.13.1 Silence Therapeutics Corporation Information
6.13.2 Silence Therapeutics RNA-based Biopharmaceuticals Description and Business Overview
6.13.3 Silence Therapeutics RNA-based Biopharmaceuticals Sales, Revenue and Gross Margin (2017-2022)
6.13.4 Silence Therapeutics RNA-based Biopharmaceuticals Product Portfolio
6.13.5 Silence Therapeutics Recent Developments/Updates
6.14 Silenseed
6.14.1 Silenseed Corporation Information
6.14.2 Silenseed RNA-based Biopharmaceuticals Description and Business Overview
6.14.3 Silenseed RNA-based Biopharmaceuticals Sales, Revenue and Gross Margin (2017-2022)
6.14.4 Silenseed RNA-based Biopharmaceuticals Product Portfolio
6.14.5 Silenseed Recent Developments/Updates
6.15 Tekmira
6.15.1 Tekmira Corporation Information
6.15.2 Tekmira RNA-based Biopharmaceuticals Description and Business Overview
6.15.3 Tekmira RNA-based Biopharmaceuticals Sales, Revenue and Gross Margin (2017-2022)
6.15.4 Tekmira RNA-based Biopharmaceuticals Product Portfolio
6.15.5 Tekmira Recent Developments/Updates
6.16 Alnylam Pharmaceuticals
6.16.1 Alnylam Pharmaceuticals Corporation Information
6.16.2 Alnylam Pharmaceuticals RNA-based Biopharmaceuticals Description and Business Overview
6.16.3 Alnylam Pharmaceuticals RNA-based Biopharmaceuticals Sales, Revenue and Gross Margin (2017-2022)
6.16.4 Alnylam Pharmaceuticals RNA-based Biopharmaceuticals Product Portfolio
6.16.5 Alnylam Pharmaceuticals Recent Developments/Updates
7 RNA-based Biopharmaceuticals Manufacturing Cost Analysis
7.1 RNA-based Biopharmaceuticals Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of RNA-based Biopharmaceuticals
7.4 RNA-based Biopharmaceuticals Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 RNA-based Biopharmaceuticals Distributors List
8.3 RNA-based Biopharmaceuticals Customers
9 RNA-based Biopharmaceuticals Market Dynamics
9.1 RNA-based Biopharmaceuticals Industry Trends
9.2 RNA-based Biopharmaceuticals Market Drivers
9.3 RNA-based Biopharmaceuticals Market Challenges
9.4 RNA-based Biopharmaceuticals Market Restraints
10 Global Market Forecast
10.1 RNA-based Biopharmaceuticals Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of RNA-based Biopharmaceuticals by Type (2023-2028)
10.1.2 Global Forecasted Revenue of RNA-based Biopharmaceuticals by Type (2023-2028)
10.2 RNA-based Biopharmaceuticals Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of RNA-based Biopharmaceuticals by Application (2023-2028)
10.2.2 Global Forecasted Revenue of RNA-based Biopharmaceuticals by Application (2023-2028)
10.3 RNA-based Biopharmaceuticals Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of RNA-based Biopharmaceuticals by Region (2023-2028)
10.3.2 Global Forecasted Revenue of RNA-based Biopharmaceuticals by Region (2023-2028)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer

List of Tables

List of Tables
Table 1. Global RNA-based Biopharmaceuticals Sales Growth Rate Comparison by Type (2022-2028) & (K Units) & (US$ Million)
Table 2. Global RNA-based Biopharmaceuticals Sales Growth Rate Comparison by Application (2022-2028) & (K Units) & (US$ Million)
Table 3. Global RNA-based Biopharmaceuticals Market Size by Region (US$ Million) (2017 VS 2021 VS 2028)
Table 4. Global RNA-based Biopharmaceuticals Market Competitive Situation by Manufacturers in 2021
Table 5. Global RNA-based Biopharmaceuticals Sales (K Units) of Key Manufacturers (2017-2022)
Table 6. Global RNA-based Biopharmaceuticals Sales Market Share by Manufacturers (2017-2022)
Table 7. Global RNA-based Biopharmaceuticals Revenue (US$ Million) by Manufacturers (2017-2022)
Table 8. Global RNA-based Biopharmaceuticals Revenue Share by Manufacturers (2017-2022)
Table 9. Global Market RNA-based Biopharmaceuticals Average Price (USD/Unit) of Key Manufacturers (2017-2022)
Table 10. Manufacturers RNA-based Biopharmaceuticals Manufacturing Sites and Area Served
Table 11. Manufacturers RNA-based Biopharmaceuticals Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global RNA-based Biopharmaceuticals by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in RNA-based Biopharmaceuticals as of 2021)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global RNA-based Biopharmaceuticals Sales by Region (2017-2022) & (K Units)
Table 16. Global RNA-based Biopharmaceuticals Sales Market Share by Region (2017-2022)
Table 17. Global RNA-based Biopharmaceuticals Revenue by Region (2017-2022) & (US$ Million)
Table 18. Global RNA-based Biopharmaceuticals Revenue Market Share by Region (2017-2022)
Table 19. North America RNA-based Biopharmaceuticals Sales by Country (2017-2022) & (K Units)
Table 20. North America RNA-based Biopharmaceuticals Sales Market Share by Country (2017-2022)
Table 21. North America RNA-based Biopharmaceuticals Revenue by Country (2017-2022) & (US$ Million)
Table 22. North America RNA-based Biopharmaceuticals Revenue Market Share by Country (2017-2022)
Table 23. Europe RNA-based Biopharmaceuticals Sales by Country (2017-2022) & (K Units)
Table 24. Europe RNA-based Biopharmaceuticals Sales Market Share by Country (2017-2022)
Table 25. Europe RNA-based Biopharmaceuticals Revenue by Country (2017-2022) & (US$ Million)
Table 26. Europe RNA-based Biopharmaceuticals Revenue Market Share by Country (2017-2022)
Table 27. Asia Pacific RNA-based Biopharmaceuticals Sales by Region (2017-2022) & (K Units)
Table 28. Asia Pacific RNA-based Biopharmaceuticals Sales Market Share by Region (2017-2022)
Table 29. Asia Pacific RNA-based Biopharmaceuticals Revenue by Region (2017-2022) & (US$ Million)
Table 30. Asia Pacific RNA-based Biopharmaceuticals Revenue Market Share by Region (2017-2022)
Table 31. Latin America RNA-based Biopharmaceuticals Sales by Country (2017-2022) & (K Units)
Table 32. Latin America RNA-based Biopharmaceuticals Sales Market Share by Country (2017-2022)
Table 33. Latin America RNA-based Biopharmaceuticals Revenue by Country (2017-2022) & (US$ Million)
Table 34. Latin America RNA-based Biopharmaceuticals Revenue Market Share by Country (2017-2022)
Table 35. Middle East and Africa RNA-based Biopharmaceuticals Sales by Country (2017-2022) & (K Units)
Table 36. Middle East and Africa RNA-based Biopharmaceuticals Sales Market Share by Country (2017-2022)
Table 37. Middle East and Africa RNA-based Biopharmaceuticals Revenue by Country (2017-2022) & (US$ Million)
Table 38. Middle East and Africa RNA-based Biopharmaceuticals Revenue Market Share by Country (2017-2022)
Table 39. Global RNA-based Biopharmaceuticals Sales by Type (2017-2022) & (K Units)
Table 40. Global RNA-based Biopharmaceuticals Sales Market Share by Type (2017-2022)
Table 41. Global RNA-based Biopharmaceuticals Revenue by Type (2017-2022) & (US$ Million)
Table 42. Global RNA-based Biopharmaceuticals Revenue Share by Type (2017-2022)
Table 43. Global RNA-based Biopharmaceuticals Price by Type (2017-2022) & (USD/Unit)
Table 44. Global RNA-based Biopharmaceuticals Sales (K Units) by Application (2017-2022)
Table 45. Global RNA-based Biopharmaceuticals Sales Market Share by Application (2017-2022)
Table 46. Global RNA-based Biopharmaceuticals Revenue by Application (2017-2022) & (US$ Million)
Table 47. Global RNA-based Biopharmaceuticals Revenue Share by Application (2017-2022)
Table 48. Global RNA-based Biopharmaceuticals Price by Application (2017-2022) & (USD/Unit)
Table 49. Pfizer Corporation Information
Table 50. Pfizer Description and Business Overview
Table 51. Pfizer RNA-based Biopharmaceuticals Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 52. Pfizer RNA-based Biopharmaceuticals Product
Table 53. Pfizer Recent Developments/Updates
Table 54. Roche Corporation Information
Table 55. Roche Description and Business Overview
Table 56. Roche RNA-based Biopharmaceuticals Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 57. Roche RNA-based Biopharmaceuticals Product
Table 58. Roche Recent Developments/Updates
Table 59. Sanofi-Aventis Corporation Information
Table 60. Sanofi-Aventis Description and Business Overview
Table 61. Sanofi-Aventis RNA-based Biopharmaceuticals Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 62. Sanofi-Aventis RNA-based Biopharmaceuticals Product
Table 63. Sanofi-Aventis Recent Developments/Updates
Table 64. Abbott Laboratories Corporation Information
Table 65. Abbott Laboratories Description and Business Overview
Table 66. Abbott Laboratories RNA-based Biopharmaceuticals Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 67. Abbott Laboratories RNA-based Biopharmaceuticals Product
Table 68. Abbott Laboratories Recent Developments/Updates
Table 69. Arrowhead Pharmaceuticals Corporation Information
Table 70. Arrowhead Pharmaceuticals Description and Business Overview
Table 71. Arrowhead Pharmaceuticals RNA-based Biopharmaceuticals Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 72. Arrowhead Pharmaceuticals RNA-based Biopharmaceuticals Product
Table 73. Arrowhead Pharmaceuticals Recent Developments/Updates
Table 74. Benitec Biopharma Corporation Information
Table 75. Benitec Biopharma Description and Business Overview
Table 76. Benitec Biopharma RNA-based Biopharmaceuticals Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 77. Benitec Biopharma RNA-based Biopharmaceuticals Product
Table 78. Benitec Biopharma Recent Developments/Updates
Table 79. Calimmune Inc Corporation Information
Table 80. Calimmune Inc Description and Business Overview
Table 81. Calimmune Inc RNA-based Biopharmaceuticals Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 82. Calimmune Inc RNA-based Biopharmaceuticals Product
Table 83. Calimmune Inc Recent Developments/Updates
Table 84. Dicerna Corporation Information
Table 85. Dicerna Description and Business Overview
Table 86. Dicerna RNA-based Biopharmaceuticals Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 87. Dicerna RNA-based Biopharmaceuticals Product
Table 88. Dicerna Recent Developments/Updates
Table 89. Gradalis Corporation Information
Table 90. Gradalis Description and Business Overview
Table 91. Gradalis RNA-based Biopharmaceuticals Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 92. Gradalis RNA-based Biopharmaceuticals Product
Table 93. Gradalis Recent Developments/Updates
Table 94. Quark Corporation Information
Table 95. Quark Description and Business Overview
Table 96. Quark RNA-based Biopharmaceuticals Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 97. Quark RNA-based Biopharmaceuticals Product
Table 98. Quark Recent Developments/Updates
Table 99. RXi Corporation Information
Table 100. RXi Description and Business Overview
Table 101. RXi RNA-based Biopharmaceuticals Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 102. RXi RNA-based Biopharmaceuticals Product
Table 103. RXi Recent Developments/Updates
Table 104. Senesco Corporation Information
Table 105. Senesco Description and Business Overview
Table 106. Senesco RNA-based Biopharmaceuticals Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 107. Senesco RNA-based Biopharmaceuticals Product
Table 108. Senesco Recent Developments/Updates
Table 109. Silence Therapeutics Corporation Information
Table 110. Silence Therapeutics Description and Business Overview
Table 111. Silence Therapeutics RNA-based Biopharmaceuticals Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 112. Silence Therapeutics RNA-based Biopharmaceuticals Product
Table 113. Silence Therapeutics Recent Developments/Updates
Table 114. Silenseed Corporation Information
Table 115. Silenseed Description and Business Overview
Table 116. Silenseed RNA-based Biopharmaceuticals Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 117. Silenseed RNA-based Biopharmaceuticals Product
Table 118. Silenseed Recent Developments/Updates
Table 119. Tekmira Corporation Information
Table 120. Tekmira Description and Business Overview
Table 121. Tekmira RNA-based Biopharmaceuticals Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 122. Tekmira RNA-based Biopharmaceuticals Product
Table 123. Tekmira Recent Developments/Updates
Table 124. Alnylam Pharmaceuticals Corporation Information
Table 125. Alnylam Pharmaceuticals Description and Business Overview
Table 126. Alnylam Pharmaceuticals RNA-based Biopharmaceuticals Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 127. Alnylam Pharmaceuticals RNA-based Biopharmaceuticals Product
Table 128. Alnylam Pharmaceuticals Recent Developments/Updates
Table 129. Production Base and Market Concentration Rate of Raw Material
Table 130. Key Suppliers of Raw Materials
Table 131. RNA-based Biopharmaceuticals Distributors List
Table 132. RNA-based Biopharmaceuticals Customers List
Table 133. RNA-based Biopharmaceuticals Market Trends
Table 134. RNA-based Biopharmaceuticals Market Drivers
Table 135. RNA-based Biopharmaceuticals Market Challenges
Table 136. RNA-based Biopharmaceuticals Market Restraints
Table 137. Global RNA-based Biopharmaceuticals Sales Forecast by Type (2023-2028) & (K Units)
Table 138. Global RNA-based Biopharmaceuticals Sales Market Share Forecast by Type (2023-2028)
Table 139. Global RNA-based Biopharmaceuticals Revenue Forecast by Type (2023-2028) & (US$ Million)
Table 140. Global RNA-based Biopharmaceuticals Revenue Market Share Forecast by Type (2023-2028)
Table 141. Global RNA-based Biopharmaceuticals Sales Forecast by Application (2023-2028) & (K Units)
Table 142. Global RNA-based Biopharmaceuticals Sales Market Share Forecast by Application (2023-2028)
Table 143. Global RNA-based Biopharmaceuticals Revenue Forecast by Application (2023-2028) & (US$ Million)
Table 144. Global RNA-based Biopharmaceuticals Revenue Market Share Forecast by Application (2023-2028)
Table 145. Global RNA-based Biopharmaceuticals Sales Forecast by Region (2023-2028) & (K Units)
Table 146. Global RNA-based Biopharmaceuticals Sales Market Share Forecast by Region (2023-2028)
Table 147. Global RNA-based Biopharmaceuticals Revenue Forecast by Region (2023-2028) & (US$ Million)
Table 148. Global RNA-based Biopharmaceuticals Revenue Market Share Forecast by Region (2023-2028)
Table 149. Research Programs/Design for This Report
Table 150. Key Data Information from Secondary Sources
Table 151. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of RNA-based Biopharmaceuticals
Figure 2. Global RNA-based Biopharmaceuticals Market Share by Type in 2021 & 2028
Figure 3. Therapeutics Product Picture
Figure 4. Vaccines Product Picture
Figure 5. Global RNA-based Biopharmaceuticals Market Share by Application in 2021 & 2028
Figure 6. Cancer
Figure 7. Diabetes
Figure 8. Tuberculosis
Figure 9. Cardiovascular Diseases
Figure 10. Others
Figure 11. Global RNA-based Biopharmaceuticals Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 12. Global RNA-based Biopharmaceuticals Market Size (2017-2028) & (US$ Million)
Figure 13. Global RNA-based Biopharmaceuticals Sales (2017-2028) & (K Units)
Figure 14. RNA-based Biopharmaceuticals Sales Share by Manufacturers in 2021
Figure 15. Global RNA-based Biopharmaceuticals Revenue Share by Manufacturers in 2021
Figure 16. The Global 5 and 10 Largest RNA-based Biopharmaceuticals Players: Market Share by Revenue in 2021
Figure 17. RNA-based Biopharmaceuticals Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021
Figure 18. Global RNA-based Biopharmaceuticals Sales Market Share by Region (2017-2022)
Figure 19. Global RNA-based Biopharmaceuticals Sales Market Share by Region in 2021
Figure 20. Global RNA-based Biopharmaceuticals Revenue Market Share by Region (2017-2022)
Figure 21. Global RNA-based Biopharmaceuticals Revenue Market Share by Region in 2021
Figure 22. U.S. RNA-based Biopharmaceuticals Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 23. Canada RNA-based Biopharmaceuticals Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 24. Germany RNA-based Biopharmaceuticals Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 25. France RNA-based Biopharmaceuticals Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 26. U.K. RNA-based Biopharmaceuticals Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 27. Italy RNA-based Biopharmaceuticals Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 28. Russia RNA-based Biopharmaceuticals Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 29. China RNA-based Biopharmaceuticals Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 30. Japan RNA-based Biopharmaceuticals Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 31. South Korea RNA-based Biopharmaceuticals Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 32. India RNA-based Biopharmaceuticals Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 33. Australia RNA-based Biopharmaceuticals Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 34. Taiwan RNA-based Biopharmaceuticals Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 35. Indonesia RNA-based Biopharmaceuticals Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 36. Thailand RNA-based Biopharmaceuticals Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 37. Malaysia RNA-based Biopharmaceuticals Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 38. Philippines RNA-based Biopharmaceuticals Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 39. Vietnam RNA-based Biopharmaceuticals Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 40. Mexico RNA-based Biopharmaceuticals Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 41. Brazil RNA-based Biopharmaceuticals Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 42. Argentina RNA-based Biopharmaceuticals Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 43. Turkey RNA-based Biopharmaceuticals Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 44. Saudi Arabia RNA-based Biopharmaceuticals Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 45. U.A.E RNA-based Biopharmaceuticals Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 46. Sales Market Share of RNA-based Biopharmaceuticals by Type (2017-2022)
Figure 47. Manufacturing Cost Structure of RNA-based Biopharmaceuticals
Figure 48. Manufacturing Process Analysis of RNA-based Biopharmaceuticals
Figure 49. RNA-based Biopharmaceuticals Industrial Chain Analysis
Figure 50. Channels of Distribution
Figure 51. Distributors Profiles
Figure 52. Bottom-up and Top-down Approaches for This Report
Figure 53. Data Triangulation
Figure 54. Key Executives Interviewed